HuGE Literature Finder
Records
1
-
5
| Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study. Lung cancer (Amsterdam, Netherlands) 2022 10 172 29-34. Lin Miaozhen, Lu Yujuan, Yu Qiwen, Chen Zebin, Peng Jiayu, Cai Xiu |
| Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China. Current medical science 2021 Feb 41 (1): 118-126. Chang Xiao-Na, Shang Fu-Mei, Jiang Hong-Yu, Chen Chen, Zhao Zhe-Yan, Deng Sheng-He, Fan Jun, Dong Xiao-Chuan, Yang Ming, Li Yan, Cai Kai-Lin, Liu Li, Liu Hong-Li, Nie X |
| Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). International journal of cancer 2021 Feb 148 (3): 682-691. Assenat Eric, Mineur Laurent, Mollevi Caroline, Lopez-Crapez Evelyne, Lombard-Bohas Catherine, Samalin Emmanuelle, Portales Fabienne, Walter Thomas, de Forges Hélène, Dupuy Marie, Boissière-Michot Florence, Ho-Pun-Cheung Alexandre, Ychou Marc, Mazard Thiba |
| Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. Journal of thrombosis and haemostasis : JTH 2015 Jun 13 (6): 998-1003. Ades S, Kumar S, Alam M, Goodwin A, Weckstein D, Dugan M, Ashikaga T, Evans M, Verschraegen C, Holmes C |
| Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study. Thrombosis research 2014 Jan 133 (1): 48-51. Corrales-Rodriguez Luis, Soulières Denis, Weng Xiaoduan, Tehfe Mustapha, Florescu Marie, Blais Norma |
- Page last reviewed:Jul 25, 2022
- Page last updated:Dec 05, 2022
- Content source: